Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 2(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01894308Phase 2Not Yet Recruiting

A Dose Ranging Study to Examine TDS-Testosterone 5%

Role: lead

NCT05159453Phase 2Not Yet Recruiting

Dose Response Study of Transdermal Human Insulin in Patients

Role: lead

NCT02733133Phase 2Unknown

Product Transference Study of Testagen™ TDS®-Testosterone

Role: lead

NCT04857320Early Phase 1Completed

Transdermal Insulin Response In Healthy Volunteers

Role: lead

NCT03544996Completed

Transdermally Delivered Human Insulin Product

Role: lead

All 5 trials loaded